PF-08049820
Sponsors
Pfizer Inc., Pfizer
Conditions
Atopic DermatitisEczema, AtopicHealthyHealthy Adults
Phase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
CompletedNCT06686797
Start: 2024-11-27End: 2026-02-23Updated: 2026-09-08
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
CompletedNCT07190430
Start: 2025-10-03End: 2025-12-15Updated: 2026-09-09
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
CompletedNCT07284173
Start: 2025-11-03End: 2025-12-18Updated: 2026-09-09
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
RecruitingNCT07597928
Start: 2026-05-13End: 2026-09-25Target: 24Updated: 2026-06-15
Phase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
RecruitingNCT07216027
Start: 2025-11-20End: 2028-02-02Target: 165Updated: 2026-09-04
C6231002 - A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Not yet recruitingCTIS2025-522965-31-00
Target: 22Updated: 2026-04-14